[{"address1": "900 North Point Parkway", "address2": "Suite 200", "city": "Alpharetta", "state": "GA", "zip": "30005", "country": "United States", "phone": "678 270 3631", "fax": "678 270 4033", "website": "https://clearsidebio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. Clearside Biomedical, Inc. has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.", "fullTimeEmployees": 36, "companyOfficers": [{"maxAge": 1, "name": "Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.", "age": 71, "title": "President, CEO & Director", "yearBorn": 1952, "fiscalYear": 2022, "totalPay": 816400, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Charles A. Deignan", "age": 59, "title": "Chief Financial Officer", "yearBorn": 1964, "fiscalYear": 2022, "totalPay": 536950, "exercisedValue": 0, "unexercisedValue": 24545}, {"maxAge": 1, "name": "Dr. Thomas A. Ciulla M.B.A., M.D.", "age": 58, "title": "Chief Medical Advisor-Retina", "yearBorn": 1965, "fiscalYear": 2022, "totalPay": 597205, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jenny R. Kobin", "age": 56, "title": "Head of Investor Relations", "yearBorn": 1967, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Rick  McElheny", "title": "Vice President of Corporate Development", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Rafael V. Andino", "age": 58, "title": "Senior Vice President of Engineering & Manufacturing", "yearBorn": 1965, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Susan L. Coultas Ph.D.", "title": "Chief Clinical Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Leslie B. Zacks", "age": 54, "title": "Secretary", "yearBorn": 1969, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.67, "open": 1.77, "dayLow": 1.64, "dayHigh": 2.07, "regularMarketPreviousClose": 1.67, "regularMarketOpen": 1.77, "regularMarketDayLow": 1.64, "regularMarketDayHigh": 2.07, "beta": 2.286, "forwardPE": -3.4827588, "volume": 1274085, "regularMarketVolume": 1274085, "averageVolume": 295373, "averageVolume10days": 785080, "averageDailyVolume10Day": 785080, "bidSize": 900, "askSize": 800, "marketCap": 150936624, "fiftyTwoWeekLow": 0.65, "fiftyTwoWeekHigh": 2.07, "priceToSalesTrailing12Months": 68.26623, "fiftyDayAverage": 1.3665, "twoHundredDayAverage": 1.10638, "currency": "USD", "enterpriseValue": 139059904, "floatShares": 57861132, "sharesOutstanding": 74721104, "sharesShort": 275405, "sharesShortPriorMonth": 183923, "sharesShortPreviousMonthDate": 1706659200, "dateShortInterest": 1709164800, "sharesPercentSharesOut": 0.0037, "heldPercentInsiders": 0.07124, "heldPercentInstitutions": 0.21234, "shortRatio": 2.03, "shortPercentOfFloat": 0.0039, "impliedSharesOutstanding": 74721104, "bookValue": -0.207, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -37316000, "trailingEps": -0.61, "forwardEps": -0.58, "enterpriseToRevenue": 62.895, "enterpriseToEbitda": -4.646, "52WeekChange": 0.9611651, "SandP52WeekChange": 0.30583346, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "CLSD", "underlyingSymbol": "CLSD", "shortName": "Clearside Biomedical, Inc.", "longName": "Clearside Biomedical, Inc.", "firstTradeDateEpochUtc": 1464874200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ea57bdfa-5d41-3e30-b431-13e72798980d", "messageBoardId": "finmb_145617165", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.02, "targetHighPrice": 8.0, "targetLowPrice": 4.0, "targetMeanPrice": 5.67, "targetMedianPrice": 5.5, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 28802000, "totalCashPerShare": 0.462, "ebitda": -29930000, "totalDebt": 41796000, "quickRatio": 5.087, "currentRatio": 5.281, "totalRevenue": 2211000, "revenuePerShare": 0.036, "returnOnAssets": -0.41617, "returnOnEquity": -13.100229, "freeCashflow": -21662500, "operatingCashflow": -24237000, "revenueGrowth": 2.229, "grossMargins": 0.74717003, "operatingMargins": -8.21187, "financialCurrency": "USD", "trailingPegRatio": null}]